CDMO Morepen Labs Secures ₹825 Crore Global Deal
Indian CDMO Morepen Laboratories has secured a multi-year global contract worth ₹825 crore (approximately $100M USD). The deal expands the company's presence in high-growth pharmaceutical segments. Execution of the contract is scheduled to begin in the first quarter of fiscal year 2027, signaling strong long-term demand in the pharma manufacturing sector.
- This deal is one of the largest single CDMO contracts in Morepen's history and is part of a strategic shift to leverage its four decades of experience in manufacturing Active Pharmaceutical Ingredients (APIs) for long-term, multi-year supply programs. Chairman and Managing Director Sushil Suri noted the deal reflects global customers' confidence in their quality systems and regulatory track record. - Morepen's core expertise lies in small molecule APIs, with a product portfolio that has included high-volume drugs like Loratadine and Montelukast. The company's R&D focuses on developing non-infringing processes and new molecules in therapeutic areas like anti-diabetic, anti-hypertensive, and cholesterol-reducing treatments. - The company's manufacturing facilities in Himachal Pradesh are accredited by major international regulatory bodies, including the USFDA, WHO-GMP, and EU authorities, which is a key factor for securing contracts from global pharmaceutical companies that are consolidating their supplier networks. - This contract comes as the Indian CDMO market is projected to grow significantly, with some forecasts suggesting it could double in the next five years, driven by a push for supply chain diversification from China and increasing demand for cost-effective manufacturing. - While Morepen's strength is in APIs, the broader Indian CDMO industry is rapidly expanding into more complex areas like biologics, biosimilars, and cell and gene therapies, investing in advanced capabilities such as single-use bioreactors to meet global demand. - The Indian pharmaceutical sector is undergoing a significant digital transformation, with wider adoption of Pharma 4.0 technologies, including automation, data analytics, and AI-driven processes to enhance manufacturing efficiency and regulatory compliance. This industry-wide push towards digitalization is creating new demands for integrated data infrastructure and lab automation. - For leadership roles, this deal highlights a key industry trend: leveraging established manufacturing strengths (like APIs) as a foundation to expand into higher-value, integrated CDMO services, a strategy that requires deep technical expertise combined with a strong grasp of global supply chain dynamics.
